MDxHealth (R): Presentation of New Data on MDxHealth's

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
35
MDxHealth (R): Presentation of New Data on MDxHealth's Prostate and Bladder Cancer Products at AUA 2018 Annual Meeting

NEWS RELEASE

Moderated posters and oral presentations feature clinical and health economic validations of SelectMDx, ConfirmMDx and prospective clinical validation of AssureMDx

IRVINE, CA, and HERSTAL, BELGIUM - 07.00 CEST , May 22, 2018 - MDxHealth SA (Euronext: MDXH.BR) announces that significant data on the performance of its SelectMDx, and ConfirmMDx tests for prostate cancer and AssureMDx test for bladder cancer were presented in two moderated posters and one podium presentation at the American Urological (AUA) Annual Meeting 18-21 May in San Francisco. Details are as follows:

Evaluation of two urinary RNA biomarker tests with an epigenetic DNA assay for the identification of men with high-grade prostate cancer Summary: Patients would greatly benefit from accurate and early identification of clinically significant prostate cancer (PCa), leading to a reduction of over-diagnosis and over-treatment. In this evaluation study, the pre- and post-biopsy RNA and DNA biomarker assays SelectMDx and ConfirmMDx outperformed the PCA3 biomarker test. Combining the urinary RNA test with the epigenetic DNA tissue test significantly improved accuracy for the identification of men with high-grade PCa. Moderated poster: MP46-11, for the full abstract and list of authors, click here .

Cost-effectiveness of SelectMDx for Prostate Cancer in Four European Countries: A modelling study Summary: The results of the study showed that by using SelectMDx in addition to serum PSA in the diagnostic pathway, Quality Adjusted Life Year (QALY)* benefits could be gained while saving healthcare costs. Cost savings varied form 129 Euro per patient in the Netherlands up to 1,217 Euro per patient in France.  Despite some differences between the countries, a resulting reduction in the prevalence of over-treatment and over-diagnosis under the current standard of care was the main factor leading to beneficial outcomes from use of SelectMDx for risk stratification. Moderated poster: MP46-20, for the abstract and list of authors, click here . *A measure of the state of health of a person or group in which the benefits, in terms of length of life, are adjusted to reflect the quality of life.

Prospective validation of a diagnostic urine test for bladder cancer: The HEMAturia study Summary: Hematuria patients comprise 20% of all referred patients in the urology clinic. Most hematuria patients will undergo an invasive cystoscopy procedure, but only 3-28% will be diagnosed with bladder cancer. In this prospective validation study of 1004 patients presenting with hematuria, the urine-based bladder cancer test improved the identification of patients most likely to benefit from cystoscopy. Importantly, these results are consistent with published studies, and further demonstrating the robustness of the test.   Podium presentation: PD66-06, For the abstract and list of authors, click here .

About MDxHealth

MDxHealth is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The company's tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, and prediction of response to a specific therapy. The Company's European headquarters are in Herstal, Belgium, with laboratory operations in Nijmegen, The Netherlands, and US headquarters and laboratory operations based in Irvine, California. For more information, visit mdxhealth.com and follow us on social media at: twitter.com/mdxhealth , facebook.com/mdxhealth and linkedin.com/company/mdxhealth .

For more information:

MDxHealth Dr. Jan Groen, CEO US: +1 949 812 6979 BE: +32 4 257 70 21 info@mdxhealth.com   LifeSpring LifeSciences Communication , Leon Melens NL: +31 6 538 16 427 lmelens@lifespring.nl
Consilium Strategic Communications Amber Fennell, Chris Welsh & Hendrik Thys UK: +44 20 3709 5701 mdxhealth@consilium-comms.com      

This press release contains forward-looking statements and estimates with respect to the anticipated future performance of MDxHealth and the market in which it operates. Such statements and estimates are based on assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable but may not prove to be correct. Actual events are difficult to predict, may depend upon factors that are beyond the company's control, and may turn out to be materially different. MDxHealth expressly disclaims any obligation to update any such forward-looking statements in this release to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based unless required by law or regulation.  This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of MDxHealth in any jurisdiction. No securities of MDxHealth may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. securities laws.

NOTE: The MDxHealth logo, MDxHealth, ConfirmMDx, SelectMDx, AssureMDx, PredictMDx and UrNCollect are trademarks or registered trademarks of MDxHealth SA. All other trademarks and service marks are the property of their respective owners. 

Attachment

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Kinross Gold Fraud Lawsuit: What Shareholders Need to Know

Updated Category News Views 18

Kinross Gold's Legal Quagmire There's a fresh storm brewing for Kinross Gold Corporation (NYSE: KGC), and it ain't the kind investors enjoy riding. You see, the company is up to its neck in a class action lawsuit, courtesy of Schall, Brown & Schwartz LLP—a big-name shareholder rights litigation outfit. The gripe? Alleged securities fraud, violating §§10(b) and 20(a)...

Continue Reading
Roche Delivers Endotrophin Assay to Nordic Bioscience Lab

Updated Category News Views 52

Roche Opens New Frontier in Diagnostic Biomarkers Get ready to chew on this: Roche Diagnostics is bringing something new to Nordic Bioscience's CLIA lab. They're offering up their Endotrophin research prototype assay on the cobas® e801 Analyzer. Now, what does this mean for the scientific world? Well, it might just shake things up for those battling cardiovascular and...

Continue Reading
Keiki Smiles Boosts Pediatric Dental Care in Waipahu

Updated Category News Views 76

A Neighborhood Dentists' Big Move: Keiki Smiles Expands in Waipahu Well, if there's one thing the dentists of Waipahu know how to do, it's adapt and grow. Keiki Smiles of Leeward, a trusted name in pediatric dentistry, just set up shop at a fresh location. The move marks a new chapter for this community staple, and honestly, it's miles more than just a longer lease and a...

Continue Reading
Biel Crystal Solidifies Position as Key iPhone UTG Supplier

Updated Category News Views 71

Biel Crystal Hones In On Foldable iPhone Tech Here's the lowdown: Apple's making waves with their first foldable phone, the iPhone Duo, and Biel Crystal? They're the rockstars cranking out that ultra-thin glass making it all possible. You might not have heard their name tossed around as much, but they're heavy hitters in the tech components scene. Biel Crystal's been...

Continue Reading
Inventor Launches Handy Solution for Kids' Car Sickness

Updated Category News Views 5

A Fresh Take on an Age-Old Problem Just when you thought the universe had thrown all it could at beleaguered parents, here comes a nifty little accessory tackling those dreaded uphill battles with kids and car rides. Some bright spark from Middleburgh, New York, sick of scrubbing car seats and clothing every other road trip, came up with a clever little invention named...

Continue Reading
Epic Legal Battle Yields $63M Verdict Against Chevron

Updated Category News Views 73

A David vs. Goliath Showdown in Court How's this for a courtroom drama? Picture eight lawyers taking on Chevron over a toxic pit buried beneath an unsuspecting family's home. These folks at Ernst Law Group and Trial Lawyers for Justice tackled Union Oil (now Chevron) and bagged a staggering $63 million for their client. This ain't your run-of-the-mill legal squabble; it's...

Continue Reading
Flagship's £100M London Move to Ignite AI Ventures

Updated Category News Views 201

London Calling: Flagship's New Venture Flagship Pioneering, the brain behind bustling biotech ventures like Moderna, is planting its flag in London. They're launching Flagship Origination Lab, U.K., their first real gig outside good ol' Cambridge, Massachusetts. They're diving in headfirst, sprinkling a whopping £100 million to brew up AI-native platform companies. And...

Continue Reading
Life Insurance: Evolving with Your Financial Journey

Updated Category News Views 56

Why Life Insurance Isn't Just a 'Set It and Forget It' Life insurance isn't some one-time deal you lock in and toss aside. Mike Newell, an insurance pro, highlights how life's shifts—whether in income, dependents, or debt—should drive tweaks to your coverage. As your life story unfolds, so too should the backbone of your financial security. Early Adulthood: Setting...

Continue Reading
AppLovin Faces Legal Heat: Investors on Edge Today

Updated Category News Views 43

AppLovin's Day of Reckoning: Investors Take Note Ever find yourself caught in a whirlwind of corporate promises that slide into disappointment? Well, buckle up, because that's exactly where AppLovin finds itself today. They've stirred up a storm with investors over some questionable hyperbole about their artificial intelligence tools and ad services. Missteps and Market...

Continue Reading
Radiate Holdco's Q3 Results: What We Know Now

Updated Category News Views 16

Digging Into Third Quarter Highlights Radiate Holdco, LLC has just thrown its third-quarter financial hat into the ring, stirring up some interest in the world of FLFO secured notes and senior notes. The folks in Princeton, N.J., sure know how to keep things exclusive—this intel is only for those holding their Notes or in the pretty exclusive club of qualified...

Continue Reading

Top 5 Most Recently Viewed Articles

Aptiv Plans Strategic Split to Strengthen Innovation and Growth

Updated Category News Views 783

Aptiv's Transformative Separation Announcement Aptiv PLC (NYSE: APTV), a pioneering technology company focused on creating a safer and more connected future, has officially unveiled plans to separate its Electrical Distribution Systems (EDS) business. This strategic decision, unanimously approved by the Board of Directors, sets the stage for both Aptiv and EDS to operate...

Continue Reading
e& Reports Strong Q3 2025 with Record Revenue and Growth

Updated Category News Views 364

Impressive Growth for e& in Q3 2025 e& has unveiled its Q3 2025 financial summary, showcasing robust growth with consolidated revenues soaring to AED 18.6 billion. This marks an impressive year-over-year growth of 29.2%. The momentum isn't just limited to the quarter; for the first nine months of 2025, the company reported consolidated revenues of AED 53.5 billion,...

Continue Reading
PARRIS Law Firm Achieves Prestigious Trial Awards for 2024 Success

Updated Category News Views 242

Acknowledging PARRIS Law Firm's Impressive Recognition in 2024 PARRIS Law Firm, renowned for its excellence in trial advocacy, has just earned multiple accolades from Top Verdict for its remarkable performances in 2024. With several No. 1 verdicts in various categories, this year marks another milestone for the firm as it stands tall among California's premier legal...

Continue Reading
Insights into the Latest Riksbank Certificate Auction Results

Updated Category News Views 232

Overview of the Riksbank Certificate Auction The recent auction conducted by the Riksbank has revealed significant details regarding certificate sales that are vital for investors and market analysts. The auction concluded successfully, showcasing the Riksbank's strategies and market engagement. Auction Details and Financial Impact Key Dates and Interest Rates The auction...

Continue Reading
Alamar Biosciences Unveils Advanced NULISAqpcr Custom Assay Kit

Updated Category News Views 205

Alamar Biosciences Introduces the NULISAqpcr™ Custom Assay Development Kit Alamar Biosciences has unveiled a significant innovation in the field of precision proteomics with the launch of the NULISAqpcr™ Custom Assay Development Kit. This groundbreaking product allows researchers to develop highly sensitive biomarker assays tailored to their specific research needs....

Continue Reading